<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912415</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-100-5</org_study_id>
    <nct_id>NCT03912415</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)</brief_title>
  <acronym>FERMATA</acronym>
  <official_title>An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy With and Without Bevacizumab Versus Placebo Plus Platinum-based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, double-blind, Phase 3 study of efficacy and safety of&#xD;
      BCD-100 plus platinum-based chemotherapy with and without bevacizumab versus placebo plus&#xD;
      platinum-based chemotherapy with and without bevacizumab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized in a 1:1 ratio to receive either Test Regimen or Comparator&#xD;
      Regimen as the first-line treatment for advanced cervical cancer. Subjects will receive study&#xD;
      therapy Q3W until progression of the disease or signs of unacceptable toxicity. In the&#xD;
      absence of dose-limiting toxicity chemotherapy should be continued for at least 6 cycles,&#xD;
      then, upon Investigator's decision and/or subjects' wish, the use of chemotherapy can be&#xD;
      stopped while maintenance therapy with BCD-100/Placebo with or without bevacizumab (depending&#xD;
      on initial therapy choice) continues until disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the date of randomization until death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) per RECIST 1.1</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the date of randomization until progression of disease according to RECIST 1.1 criteria or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) per iRECIST</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the date of randomization until progression of disease according to iRECIS criteria or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate per (ORR) RECIST 1.1</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of the participants who have a Complete Response or a Partial Response as assessed by a blind independent central reviewer per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) per iRECIST</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of the participants who have a Complete Response or a Partial Response as assessed by a blind independent central reviewer per iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of the participants who have a Complete Response, a Partial Response or a Stable DIsease as assessed by a blind independent central reviewer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>1 year</time_frame>
    <description>TTR will be calculated from the randomization date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>DOR will be calculated from the moment of registration of response till event (progression or death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>BCD-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCD-100 3 mg/kg Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-100</intervention_name>
    <description>Anti-PD-1 monoclonal antibody, IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (or Carboplatin)</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signing an IRB/EC-approved informed consent&#xD;
&#xD;
          2. Females ≥ 18 years of age on day of signing informed consent&#xD;
&#xD;
          3. Histologically confirmed squamous carcinoma of the cervix&#xD;
&#xD;
          4. Progressing thru or recurrent disease treated for curative intent or primary&#xD;
             metastatic cervical cancer stage FIGO IVB&#xD;
&#xD;
          5. Agreement to newly obtained core or excisional biopsy of a tumor lesion not previously&#xD;
             irradiated for determination of PD-L1 status prior to randomization (using archival&#xD;
             biopsy material is only acceptable in subjects in whom obtaining a new sample is&#xD;
             contraindicated)&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          7. For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or to use a contraceptive method with a failure rate of &lt; 1%&#xD;
             per year from the moment of signing informed consent, during the treatment period and&#xD;
             at least 6 months after administration of the last dose of study drug. A woman is&#xD;
             considered to be of childbearing potential if she is postmenarcheal, has not reached a&#xD;
             postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause&#xD;
             other than menopause), and has not undergone surgical sterilization (removal of&#xD;
             ovaries, fallopian tubes, and/or uterus). Examples of contraceptive methods with a&#xD;
             failure rate of &lt; 1% per year include but are not limited to bilateral tubal ligation&#xD;
             and/or occlusion, male sterilization, and intrauterine devices. The reliability of&#xD;
             sexual abstinence should be evaluated in relation to the duration of the clinical&#xD;
             study and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g.,&#xD;
             calendar, ovulation, symptothermal, or postovulation methods) is not acceptable method&#xD;
             of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Indications for potentially curative treatment (surgery or radiation therapy)&#xD;
&#xD;
          2. Prior systemic treatment for recurrent, secondarily progressive or initially&#xD;
             metastatic disease&#xD;
&#xD;
          3. Previous use of chemotherapy other than initial treatment for curative intent (e.g.&#xD;
             chemotherapy used concurrently with radiation therapy, neoadjuvant or consolidation&#xD;
             chemotherapy cycles before radiotherapy or 2 chemotherapy cycles after completion of&#xD;
             chemoradiotherapy are allowed)&#xD;
&#xD;
          4. Contraindications to cisplatin, carboplatin, paclitaxel, or bevacizumab&#xD;
&#xD;
          5. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.&#xD;
             Participants with known brain metastases may participate provided that the brain&#xD;
             metastases have been previously treated with radiotherapy or surgery only and are&#xD;
             radiographically stable&#xD;
&#xD;
          6. Concomitant diseases or conditions which pose a risk of AE development during study&#xD;
             treatment:&#xD;
&#xD;
               1. uncontrolled hypertension, defined as systolic &gt; 150 mm Hg or diastolic &gt; 90 mm&#xD;
                  Hg;&#xD;
&#xD;
               2. stable angina functional class III-IV;&#xD;
&#xD;
               3. unstable angina or myocardial infarction less than 6 months prior to&#xD;
                  randomization;&#xD;
&#xD;
               4. NYHA Grade III-IV congestive heart failure;&#xD;
&#xD;
               5. serious cardiac arrhythmia requiring medication (subjects with asymptomatic&#xD;
                  atrial fibrillation can be enrolled if controlled ventricular rate);&#xD;
&#xD;
               6. atopic asthma, Stage III-IV COPD, angioedema;&#xD;
&#xD;
               7. severe respiratory failure;&#xD;
&#xD;
               8. any other diseases which pose unacceptable risk of AE development during study&#xD;
                  treatment in Investigator's opinion.&#xD;
&#xD;
          7. Active or known or suspected autoimmune disease (subjects with Type 1 diabetes&#xD;
             mellitus, hypothyroidism only requiring hormone replacement, or skin disorders&#xD;
             (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to&#xD;
             enroll).&#xD;
&#xD;
          8. Condition requiring systemic treatment with either corticosteroids or other&#xD;
             immunosuppressive medications within 14 days prior to randomization.&#xD;
&#xD;
          9. History of (non-infectious) pneumonitis that required corticosteroids or current&#xD;
             pneumonitis&#xD;
&#xD;
         10. Neutrophils &lt;1500/mcl or platelets &lt;100 000/mcl or hemoglobin &lt;90 g/l.&#xD;
&#xD;
         11. Creatinine ≥ 1.5 x UNL.&#xD;
&#xD;
         12. Bilirubin ≥ 1.5 x UNL (excluding Gilbert's syndrome if bilirubin &lt; 50 µmol/l) or&#xD;
             AST/ALT ≥ 3 x UNL (excluding subjects with liver metastases if AST/ALT &lt; 5 x UNL) or&#xD;
             alkaline phosphatase ≥ 2.5 x UNL.&#xD;
&#xD;
         13. Chemotherapy or radiation therapy less than 28 days prior to randomization.&#xD;
&#xD;
         14. Major surgery procedure less than 28 days prior to randomization.&#xD;
&#xD;
         15. Previous use of PD-1/PD-L1/PD-L2 agent or another agent directed to stimulatory or&#xD;
             co-inhibitory T-cell receptor (e.g. CTLA-4, OX 40, CD137).&#xD;
&#xD;
         16. Previous use of VEGF/VEGFR inhibitors, including bevacizumab, ramucirumab, aflibercept&#xD;
             and tyrosine kinase inhibitors.&#xD;
&#xD;
         17. Prior invasive malignancy with any evidence of disease within the last 3 years.&#xD;
             Subjects with non-melanoma skin cancer or carcinoma in situ (e.g. breast cancer) who&#xD;
             have undergone potentially curative therapy are not excluded.&#xD;
&#xD;
         18. Pre-existing clinically significant (≥ grade 2) peripheral neuropathy or hearing&#xD;
             impairment&#xD;
&#xD;
         19. Any conditions or circumstances that limit subject's ability to comply with protocol&#xD;
             requirements&#xD;
&#xD;
         20. Active hepatitis B, active hepatitis С or history of positive HIV.&#xD;
&#xD;
         21. Active infection requiring therapy or systemic antibiotics use less than 14 days prior&#xD;
             to enrollment. Severe infections within 28 days prior to first study drug&#xD;
             administration.&#xD;
&#xD;
         22. Administration of a live vaccine within 28 days prior to enrollment&#xD;
&#xD;
         23. Current using of another investigational device or drug study, or less than 30 days&#xD;
             since ending of using of another investigational device or drug study&#xD;
&#xD;
         24. Life expectancy less than 12 weeks&#xD;
&#xD;
         25. Significant adverse events (AE) of previous therapy excluding chronic and/or&#xD;
             irreversible events which cannot affect study drug safety evaluation (e.g. alopecia)&#xD;
&#xD;
         26. Known hypersensitivity or allergy to paclitaxel, cisplatin, carboplatin, bevacizumab,&#xD;
             BCD-100 or any of their excipients. Known hypersensitivity or allergy to drugs derived&#xD;
             from Chinese hamster (CHO) ovary cells or history of severe allergic, anaphylactic, or&#xD;
             other hypersensitivity reactions to chimeric or humanized antibodies or fusion&#xD;
             proteins.&#xD;
&#xD;
         27. Pregnancy or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yulia N Linkova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director of Clinical Development Department, BIOCAD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergey N Fogt, MD, PhD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fedor B Krykov, MD, PhD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng-yu Lu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>High technology Hospital Medcenter</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamta Makharadze, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acad. F.Todua Medical center &quot;Research institute of Clinical Medicine&quot;</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Melkadze, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>High Technology Medical Centre, University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Gogishvili, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Personalized Medicine Ltd.</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Tavartkiladze, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Oncology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gia Nemsadze, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LEPL First University Clinic of Tbilisi State Medical University</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nana Chikhladze, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Clinic Consilium Medulla</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Karsimashvili, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neo Medi</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikheil Shavdia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital No. 5</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis A Tancyirev, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Oncology Center</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry E Emelyanov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruslan A Zukov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Scientific and Practical Center named A.S. Loginova</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludmila G Zhukova, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin National Medical Research Center of Oncology (2)</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena V Artamonova, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Moscow City Oncology Hospital № 62&quot; Moscow Health Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniil Stroyakovsky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Murmansk Regional Clinical Hospital named after P.A. Bayandina</name>
      <address>
        <city>Murmansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny A Fomin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail V Dvorkin, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC &quot;New Clinic&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valery M Chistyakov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AV Medical Group</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timur T Andabekov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Modern Medical Technologies&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana V Odintsova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Petrov National Medical Research Center of Oncology (2)</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adilia F Urmancheeva, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir M Moiseenko, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Educational Institution of Higher Professional Education &quot;Mordovia State University N.P. Ogareva &quot;</name>
      <address>
        <city>Saransk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Skopin, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Clinical Oncology Center</name>
      <address>
        <city>Stavropol'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana N Shkodenko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay V Kislov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Şişli Istanbul</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fazilet E Dinsbas, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Georgia</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

